title: [Setting up a department of molecular pathology in oncology in a pathology laboratory (LPCE, CHU de Nice)].
abstract: The advent of targeted therapies and personalized medicine in oncology has led in France to the settlement and organisation of a network of hospital molecular genetic platforms under the impetus of the National Cancer Institute (INCa). These platforms are, according to the concerned sites, integrated or not in pathology laboratories. The development of molecular biology methods, the choice of the procedures, the establishment of sample workflow, the quality control and the selection of the genomic alterations to be detected on each platform, have been left to the discretion of the different laboratories. Based on calls for project made by the INCa, hospital molecular genetic platforms were able to adapt their activity according to the assigned budgets. While the presence of some genomic alterations (i.e. KRAS gene mutations in metastatic colon adenocarcinoma or EGFR gene mutations in lung adenocarcinomas), may lead to administration of targeted therapies under the Marketing Authorization Application (MAA), others are associated with therapeutic clinical trials. However, increasing number of MAA for new molecules targeting genomic alterations is likely in the near future. In this context, it is necessary to quickly adapt the organisation of work of the hospital pathology laboratories performing molecular biology tests in order to meet the growing demand of oncologists in the field of targeted therapies. The purpose of this article is to describe the different steps of the settlement of a molecular genetic platform in an academic pathology laboratory (LPCE, CHU de Nice) and to show the experience of this laboratory specifically oriented on the support of the morphological and molecular diagnosis of lung cancer, thyroid cancer and malignant melanoma.
authors.affiliation: Laboratoire de pathologie clinique et expérimentale (LPCE), hôpital Pasteur, centre hospitalo-universitaire, BP 69, 06002 Nice, France.
authors.forename: Elodie
authors.initials: E
authors.lastname: Long
authors.forename: Véronique
authors.initials: V
authors.lastname: Hofman
authors.forename: Marius
authors.initials: M
authors.lastname: Ilie
authors.forename: Virgine
authors.initials: V
authors.lastname: Lespinet
authors.forename: Christelle
authors.initials: C
authors.lastname: Bonnetaud
authors.forename: Olivier
authors.initials: O
authors.lastname: Bordone
authors.forename: Virginie
authors.initials: V
authors.lastname: Gavric-Tanga
authors.forename: Kevin
authors.initials: K
authors.lastname: Washetine
authors.forename: Marie-Clotilde
authors.initials: MC
authors.lastname: Gaziello
authors.forename: Virginie
authors.initials: V
authors.lastname: Mauro
authors.forename: Sandra
authors.initials: S
authors.lastname: Lassalle
authors.forename: Eric
authors.initials: E
authors.lastname: Selva
authors.forename: Katia
authors.initials: K
authors.lastname: Zahaf
authors.forename: José
authors.initials: J
authors.lastname: Santini
authors.forename: Laurent
authors.initials: L
authors.lastname: Castillo
authors.forename: Jean-Philippe
authors.initials: JP
authors.lastname: Lacour
authors.forename: Nicolas
authors.initials: N
authors.lastname: Vénissac
authors.forename: Jérôme
authors.initials: J
authors.lastname: Mouroux
authors.forename: Josiane
authors.initials: J
authors.lastname: Otto
authors.forename: Michel
authors.initials: M
authors.lastname: Poudenx
authors.forename: Charles-Hugo
authors.initials: CH
authors.lastname: Marquette
authors.forename: Jean-Christophe
authors.initials: JC
authors.lastname: Sabourin
authors.forename: Paul
authors.initials: P
authors.lastname: Hofman
mesh_terms: D005602:France; D006801:Humans; D007753:Laboratories / Q000458:organization & administration*; D008495:Medical Oncology; D057089:Pathology, Molecular; D017410:Practice Guidelines as Topic; D011996:Records